We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
76
DELISTED
Agile Therapeutics
AGRX
$15.3M 0.22%
7,960
– –
ADMA icon
77
ADMA Biologics
ADMA
$2.02B
$15M 0.22%
13,262,375
-3,322,427
-20% -$4.65M
HCAQ
78
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$14.8M 0.22%
1,500,000
– –
IMCR icon
79
Immunocore
IMCR
$1.7B
$14.8M 0.22%
400,000
– –
LENZ
80
LENZ Therapeutics
LENZ
$179M
$14.3M 0.21%
125,013
– –
ACRS icon
81
Aclaris Therapeutics
ACRS
$715M
$14.1M 0.2%
781,236
-68,764
-8% -$1.1M
BIIB icon
82
Biogen
BIIB
$30.9B
$13.8M 0.2%
+48,600
New +$15.9M
VTRS icon
83
Viatris
VTRS
$20.8B
$13.6M 0.2%
1,004,419
– –
DAWN
84
DELISTED
Day One Biopharmaceuticals
DAWN
$13.2M 0.19%
556,047
-200,000
-26% -$4.79M
CMLTU
85
DELISTED
CM Life Sciences III Inc. Unit
CMLTU
$12.8M 0.19%
1,250,000
– –
PODD icon
86
Insulet
PODD
$11.8B
$12.7M 0.18%
+44,522
New +$12.7M
NBTX
87
Nanobiotix
NBTX
$1.92B
$12M 0.17%
1,059,800
– –
ADPT icon
88
Adaptive Biotechnologies
ADPT
$3.61B
$12M 0.17%
352,804
– –
ACCD
89
DELISTED
Accolade Inc
ACCD
$11.8M 0.17%
279,774
+34,033
+14% +$1.6M
ZY
90
DELISTED
Zymergen Inc. Common Stock
ZY
$11.6M 0.17%
883,332
-750,000
-46% -$15.9M
CLOV icon
91
Clover Health Investments
CLOV
$2.23B
$11.1M 0.16%
1,500,000
– –
ONEM
92
DELISTED
1Life Healthcare
ONEM
$10.8M 0.16%
532,350
+16,306
+3% +$419K
KYMR icon
93
Kymera Therapeutics
KYMR
$8.66B
$10.6M 0.15%
+180,000
New +$10.4M
ONCR
94
DELISTED
Oncorus, Inc.
ONCR
$10.3M 0.15%
1,099,810
-363,789
-25% -$4.15M
FDMT icon
95
4D Molecular Therapeutics
FDMT
$502M
$10.1M 0.15%
375,256
– –
SMIHU
96
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
$10.1M 0.15%
1,000,000
– –
BLSA
97
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$9.96M 0.14%
1,000,000
– –
FUSN
98
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$9.94M 0.14%
1,254,607
-520,560
-29% -$4.38M
RACB
99
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$9.85M 0.14%
1,000,000
– –
PNT
100
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$9.56M 0.14%
1,242,879
-257,121
-17% -$2.35M
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.